Clinical trials: Early Alzheimers Disease
Mild Cognitive Impairment, Alzheimer Disease
Neurofeedback as a Novel Treatment for Mild Cognitive Impairment & Early Alzheimer's Disease
This study protocol proposes an EEG based neurofeedback (EEG-NFB) technique to upregulate the posterior cingulate cortex (PCC) in patients suffering from mild cognitive impairment (MCI) and early Alzheimer's disease (AD).
- Trial name
- NCT02987842
- Testing
- TruScan Neurofeedback
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Beersheva Mental Health Center
Alzheimer's Disease, Mild Cognitive Impairment
BEAM: Brain-Eye Amyloid Memory Study
The main objectives for this study are: 1. To investigate novel, non-invasive ocular measurements including optical coherence tomography and eye tracking in a cross-sectional study of participants with various neurodegenerative…
- Conditions
- Alzheimer's Disease, Mild Cognitive Impairment, Vascular Cognitive Impairment, Parkinson's Disease
- Trial name
- BEAM (NCT02524405)
- Testing
- Pittsburgh Compound B [11C]-PIB
- Where
- 5 sites in Canada
- Volunteers
- 345 people, healthy volunteers welcome
- Sponsor
- Sunnybrook Health Sciences Centre
Amyloidosis, Amyloid Cardiomyopathy
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Transthyretin amyloidosis (ATTR) is a disease where the normally occurring transthyretin (TTR) protein falls apart and forms amyloid, a sticky plaque-like substance that accumulates in different organs in the body and can cause…
- Conditions
- Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis, Cardiomyopathies
- Trial name
- NCT06563895
- Testing
- Acoramidis
- Where
- 104 sites in United States, Argentina and 22 more
- Volunteers
- 587 people
- Sponsor
- Eidos Therapeutics, a BridgeBio company
Alzheimer Disease
Safety and Efficacy of Plasma Transfusion From Exercise-trained Donors in Patients With Early Alzheimer's Disease
Introduction Given that exercise training reduces the risk of developing Alzheimer's disease (AD), induces changes in the blood composition and has widespread systemic benefits, it is reasonable to hypothesize that exercised…
- Trial name
- ExPlas (NCT05068830)
- Testing
- ExPlas, Octaplasma, Saline
- Where
- Norway
- Volunteers
- 60 people
- Sponsor
- Norwegian University of Science and Technology
Mild Cognitive Impairment, Alzheimer's Disease
Alzheimer's Disease Neuroimaging Initiative Grand Opportunity
The purpose of this study is to build upon the information obtained in the original Alzheimer's Disease Neuroimaging Initiative (ADNI1), to examine how brain imaging technology can be used with other tests to measure the…
- Trial name
- ADNI-GO (NCT01078636)
- Where
- 55 sites in United States, Canada
- Volunteers
- 342 people, healthy volunteers welcome
- Sponsor
- Alzheimer's Disease Cooperative Study (ADCS)
Alzheimer's Disease, Cognition Disorders
Study of Repetitive Transcranial Magnetic Stimulation (rTMS) as add-on Treatment for Early Alzheimer's Disease
The aim is to examine the effect of Repetitive Transcranial Magnetic Stimulation (rTMS) applied at the anodic left Cortex DorsoLateral PreFrontal (CDLPF) of patients with early Alzheimer's disease (AD).
- Trial name
- ALSTIMAG (NCT01481961)
- Testing
- repetitive Transcranial Magnetic Stimulation (rTMS)
- Where
- France
- Volunteers
- 15 people
- Sponsor
- Pierre Vandel, MD PhD
Alzheimer Disease, Early Onset, Alzheimer Disease
Study of Tolerability, Safety and Efficacy of Sensory Stimulation at Multiple Dose Levels to Improve Brain Function (Etude Study)
The Etude Study is a multi-center, four-arm prospective dose-adjusting study designed to assess the tolerability, safety and efficacy of non-invasive sensory stimulation for patients with cognitive impairment.
- Conditions
- Alzheimer Disease, Early Onset, Alzheimer Disease, Alzheimer Dementia, Mild Cognitive Impairment
- Trial name
- NCT03661034
- Testing
- GammaSense Stimulation System (non-invasive, non-significant risk)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Cognito Therapeutics, Inc.
Alzheimer's Disease
A Post Marketing Study in Participants With Early Alzheimer's Disease Treated With Lecanemab
The primary purpose of this study is to investigate the characteristics of amyloid related imaging abnormalities (ARIA) and investigate the treatment continuation status (e.g., continuation, interruption) after the onset of ARIA…
- Trial name
- NCT06322667
- Testing
- No Intervention
- Where
- 3 sites in Japan
- Volunteers
- 5,000 people
- Sponsor
- Eisai Co., Ltd.
Mild Cognitive Impairment Due to Alzheimer's Disease, Dementia Due to Alzheimer's Disease (Disorder)
Biomarkers of Cognitive Impairment in Blood Cells
The aim of this study is to identify transcriptomic biomarkers in blood cells to diagnose early cognitive impairment. This would allow preventing the development of severe pathologies, such as Alzheimer Disease.
- Trial name
- COGNIMARK (NCT05582941)
- Testing
- No intervention will be performed.
- Where
- Spain
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- University of the Balearic Islands
Mild Cognitive Impairment, Alzheimer Disease
Alzheimer's Disease Neuroimaging Initiative 4
The Alzheimer's Disease Neuroimaging Initiative 4 (ADNI4) is a non-randomized, longitudinal, natural history study designed to validate biomarkers, improve clinical trial design, and advance understanding of Alzheimer's disease…
- Conditions
- Mild Cognitive Impairment, Alzheimer Disease, Dementia
- Trial name
- ADNI4 (NCT05617014)
- Testing
- Neuraceq, Amyvid, Tauvid
- Where
- 65 sites in United States, Canada
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- University of Southern California